These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34427103)

  • 1. Potential policy reforms to strengthen the accelerated approval pathway.
    Kaltenboeck A; Mehlman A; Pearson SD
    J Comp Eff Res; 2021 Nov; 10(16):1177-1186. PubMed ID: 34427103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reforming Reimbursement for the US Food and Drug Administration's Accelerated Approval Program to Support State Medicaid Programs.
    Sachs RE; Donohue JM; Dusetzina SB
    JAMA Health Forum; 2022 Nov; 3(11):e224115. PubMed ID: 36399351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval.
    Neumann PJ; Crummer E; Chambers JD; Tunis SR
    Milbank Q; 2023 Dec; 101(4):1047-1075. PubMed ID: 37644739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Great Trees Require Strong Roots: Evaluating Data and Delegation Doctrine Underlying Proposed Reforms to FDA's Accelerated Approval Program.
    Deshmukh AD
    J Law Med Ethics; 2023; 51(4):920-925. PubMed ID: 38477271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extending the US Food and Drug Administration's Postmarket Authorities.
    Fernandez Lynch H; Sachs RE; Lee S; Herder M; Ross JS; Ramachandran R
    JAMA Health Forum; 2023 Jun; 4(6):e231313. PubMed ID: 37294583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicaid and Accelerated Approval: Spending on Drugs with and without Proven Clinical Benefits.
    Sachs RE; Jazowski SA; Gavulic KA; Donohue JM; Dusetzina SB
    J Health Polit Policy Law; 2022 Dec; 47(6):673-690. PubMed ID: 35867545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural Reform.
    Herder M
    J Law Med Ethics; 2023; 51(4):900-919. PubMed ID: 38477277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of FDA's Accelerated Approval Program Performance December 1992-December 2021.
    Beakes-Read G; Neisser M; Frey P; Guarducci M
    Ther Innov Regul Sci; 2022 Sep; 56(5):698-703. PubMed ID: 35900722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.
    Gyawali B; Hey SP; Kesselheim AS
    JAMA Intern Med; 2019 Jul; 179(7):906-913. PubMed ID: 31135808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What Commissioner Gottlieb's FDA Is Doing to Lower Prescription Drug Prices and Steps Congress Can Take to Help.
    Waxman H; Corr B; Martin K; Duong S
    Issue Brief (Commonw Fund); 2018 Apr; 2018():1-10. PubMed ID: 29992802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018.
    Ribeiro TB; Buss L; Wayant C; Nobre MRC
    PLoS One; 2020; 15(7):e0236345. PubMed ID: 32706800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The next generation of rare disease drug policy: ensuring both innovation and affordability.
    Pearson C; Schapiro L; Pearson SD
    J Comp Eff Res; 2022 Oct; 11(14):999-1010. PubMed ID: 35946484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval.
    Sachs RE; Gavulic KA; Donohue JM; Dusetzina SB
    JAMA Health Forum; 2021 Oct; 2(10):e213177. PubMed ID: 35977163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease.
    Dhruva SS; Kesselheim AS; Woloshin S; Ji RZ; Lu Z; Darrow JJ; Redberg RF
    Clin Pharmacol Ther; 2023 Sep; 114(3):614-617. PubMed ID: 37218658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA's Flexibility in Subpart H Approvals: Assessing Quantum of Effectiveness Evidence.
    Sasinowski FJ; Varond AJ
    Food Drug Law J; 2016 Aug; 71(1):135-157. PubMed ID: 29693934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The FDA Struggle to Withdraw Makena: Problems With the Accelerated Approval Process.
    Aaron DG; Cohen IG; Adashi EY
    JAMA; 2022 Dec; 328(24):2394-2395. PubMed ID: 36480209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA reform in Congress: FDA's concerns. Food and Drug Administration.
    James JS
    AIDS Treat News; 1996 Apr; (no 245):5-7. PubMed ID: 11363624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.